Followers | 9840 |
Posts | 260002 |
Boards Moderated | 4 |
Alias Born | 12/27/2006 |
Wednesday, January 16, 2019 5:40:07 PM
Link to Video - click here to watch the technical chart video
Recent ALRN News
- Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million • GlobeNewswire Inc. • 05/03/2024 08:05:00 PM
- Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million • GlobeNewswire Inc. • 05/01/2024 12:45:03 PM
- Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) • GlobeNewswire Inc. • 05/01/2024 12:30:23 PM
- Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 04/15/2024 09:20:25 PM
- Aileron Therapeutics Announces CEO Transition • GlobeNewswire Inc. • 03/12/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:01:03 PM
- Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event • GlobeNewswire Inc. • 02/15/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 12:01:03 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/06/2024 05:15:26 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/05/2024 06:20:21 PM
- Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024 • GlobeNewswire Inc. • 02/01/2024 09:30:50 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/31/2024 09:05:32 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/29/2024 09:15:07 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/29/2024 09:10:06 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/29/2024 01:46:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 01:14:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 12:00:32 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 01/19/2024 09:44:28 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/11/2024 09:18:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 09:08:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/18/2023 10:56:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 09:43:12 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM